



HAL
open science

Peptide-Based Inhibitors Of The Phagocyte Nadph Oxidase

Jamel El-Benna, Pham My-Chan Dang, Axel Périanin

► **To cite this version:**

Jamel El-Benna, Pham My-Chan Dang, Axel Périanin. Peptide-Based Inhibitors Of The Phagocyte Nadph Oxidase. *Biochemical Pharmacology*, 2010, 80 (6), pp.778. 10.1016/j.bcp.2010.05.020 . hal-00608935

HAL Id: hal-00608935

<https://hal.science/hal-00608935>

Submitted on 16 Jul 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Peptide-Based Inhibitors Of The Phagocyte NADPH Oxidase

Authors: Jamel El-Benna, Pham My-Chan Dang, Axel Périanin



PII: S0006-2952(10)00359-X
DOI: doi:10.1016/j.bcp.2010.05.020
Reference: BCP 10575

To appear in: *BCP*

Received date: 30-3-2010
Revised date: 14-5-2010
Accepted date: 17-5-2010

Please cite this article as: El-Benna J, Dang PM-C, Périanin A, Peptide-Based Inhibitors Of The Phagocyte NADPH Oxidase, *Biochemical Pharmacology* (2008), doi:10.1016/j.bcp.2010.05.020

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

PEPTIDE-BASED INHIBITORS OF THE PHAGOCYTE NADPH OXIDASE**Jamel El-Benna¹, Pham My-Chan Dang¹, and Axel Périanin^{1,2}**

¹INSERM, U773, F-75018, France; Université Paris 7 Denis Diderot, Faculté de Médecine, site Bichat, Paris, F-75018, France. ²Institut Cochin, Université Paris 5 Descartes, CNRS (UMR 8104), Paris, France, Inserm, U1016, Paris, France.

Corresponding author: Dr Jamel El-Benna, INSERM U773, CRB3, Faculté de Médecine Xavier Bichat, 16 rue Henri Huchard, 75018 Paris France.

Tel: 33 1 57 27 74 72; Fax: 33 1 57 27 74 61; E-mail: jamel.elbenna@inserm.fr

The authors have no competing interests to declare.

Running title: NADPH oxidase-derived peptide inhibitors

Abbreviations: DPI, diphenylene iodonium; CGD, chronic granulomatous disease, fMLF, formyl-methionyl-leucyl-phenylalanine; MPO, Myeloperoxidase; phox, phagocyte oxidase; ROS, reactive oxygen species

ABSTRACT

Phagocytes such as neutrophils, monocytes and macrophages play an essential role in host defenses against pathogens. To kill these pathogens, phagocytes produce and release large quantities of antimicrobial molecules such as reactive oxygen species (ROS), microbicidal peptides, and proteases. The enzyme responsible for ROS generation is called NADPH oxidase, or respiratory burst oxidase, and is composed of six proteins: gp91phox, p22phox, p47phox, p67phox, p40phox and Rac1/2. The vital importance of this enzyme in host defenses is illustrated by a genetic disorder called chronic granulomatous disease (CGD), in which the phagocyte NADPH oxidase is dysfunctional, leading to life-threatening recurrent bacterial and fungal infections. However, excessive NADPH oxidase activation and ROS overproduction can damage surrounding tissues and participate in exaggerated inflammatory processes. As ROS production is believed to be involved in several inflammatory diseases, specific phagocyte NADPH oxidase inhibitors might have therapeutic value. In this commentary, we summarize the structure and activation of the phagocyte NADPH oxidase, and describe pharmacological inhibitors of this enzyme, with particular emphasis on peptide-based inhibitors derived from gp91phox, p22phox and p47phox.

Key words: Phagocytes, NADPH-oxidase, inhibitors, gp91phox/NOX2, p22phox, p47phox

1. Introduction

Reactive oxygen species (ROS) produced by phagocytes are one of the most powerful host defenses against bacteria, yeasts and fungi [1, 2]. ROS produced by phagocytes include superoxide anion ($O_2^{\cdot-}$), hydrogen peroxide (H_2O_2), hydroxyl radical (OH°) and hypochlorous acid ($HOCl$). These ROS are produced in large quantities when phagocytes are stimulated by pro-inflammatory agents or by particles such as bacteria. This process, known as the "oxidative burst" or "respiratory burst", is characterized by a rapid, cyanide-insensitive increase in oxygen uptake and glucose consumption [1, 2]. Superoxide anion ($O_2^{\cdot-}$), the precursor of the other ROS, is first produced by an enzyme called NADPH oxidase, as follows [2, 3]:



Once produced, $O_2^{\cdot-}$ is immediately transformed into H_2O_2 by spontaneous dismutation at acid pH in the phagosome, or through enzymatic dismutation by superoxide dismutase in the cytosol. Interaction between H_2O_2 and $O_2^{\cdot-}$ can, through the Haber-Weiss reaction in the presence of a transition metal (or the Fenton reaction in the presence of iron), give rise to the hydroxyl radical (OH°), one of the most powerful oxidants. H_2O_2 is also a substrate of myeloperoxidase, an enzyme stored in neutrophil azurophilic granules and released during neutrophil activation. Myeloperoxidase catalyses the transformation of H_2O_2 , in the presence of a halogen (Cl^- , Br^- , I^-), into highly toxic molecules such as hypochlorous acid ($HOCl$). Other reactions between OCl^-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

and H₂O₂ can lead to the formation of singlet oxygen (¹O₂). Most of the hypochlorous acid (OCl⁻) thus generated is converted into toxic chloramines. MPO can also use H₂O₂ to oxidize tyrosines into tyrosyl radicals. HOCl-, chloramines and tyrosyl radicals, which are toxic species that serve to kill bacteria and other pathogens. The crucial role of phagocyte NADPH oxidase in host defenses against microbial pathogens is illustrated by a human genetic disorder called chronic granulomatous disease, which is associated with life-threatening recurrent bacterial and fungal infections [4]. However, excessive ROS production can damage healthy bystander tissues. ROS hyperproduction by neutrophils is believed to cause direct tissue insult in a broad range of inflammatory diseases, including rheumatoid arthritis, inflammatory bowel diseases, acute respiratory distress syndrome, sepsis, diabetic complications, cardiovascular disease, ischemic tissue injury and neurodegenerative diseases [5, 6]. Pharmacological NADPH oxidase inhibition might therefore be beneficial in patients with these disorders. Currently, there are no specific inhibitors of the phagocyte NADPH oxidase. Peptide-based inhibitors derived from specific subunits of the enzyme could provide a certain degree of specificity. In the first part of this manuscript, we review the principal features of NADPH oxidase in order to provide the information necessary to understand the action of the inhibitory peptides described in the second part.

2. Components of the phagocyte NADPH oxidase

The phagocyte NADPH oxidase is a multicomponent enzyme complex comprising six proteins, namely p22phox (phox: phagocyte oxidase), gp91phox, p47phox, p67phox,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

5

p40phox and the small G-protein Rac1 or Rac2. In resting cells the NADPH oxidase is inactive because its components are distributed between the cytosol (p47phox, p67phox, p40phox and Rac1/2) and the plasma membrane and membranes of specific granules (p22phox and gp91phox/NOX2, which form the flavocytochrome b₅₅₈). When cells are activated, the cytosolic components migrate to the membranes, where they associate with the membrane-bound components to assemble the catalytically active oxidase [7, 8].

Flavocytochrome b₅₅₈ is the central membrane-bound component of NADPH oxidase [9]. It is composed of a 1:1 complex between a glycosylated 91-kDa protein subunit (gp91phox) of 570 amino acids (Figure 1), and a non glycosylated 22-kDa subunit (p22phox) of 195 amino acids (Figure 2). Flavocytochrome b₅₅₈ contains one FAD and two hemes and forms the NADPH oxidase electron transfer chain [9]. It serves as the central docking station for the cytosolic components, via numerous interaction sites [8]. P22phox is phosphorylated on threonine residues by a phosphatidic acid-activated kinase and PKC [10]. Gp91phox phosphorylation in human neutrophils enhances its enzymatic activity and its binding to p47phox, p67phox and Rac1 [11].

P47phox is a cytosolic protein composed of 390 amino acids. Its COOH-terminal sequence is very basic and rich in serine and arginine [12, 13]. The amino acid sequence of p47phox also contains two src-homology 3 (SH3) domains, one phox homology (PX) domain, a proline-rich region and one autoinhibitory region (AIR) (Figure 3). P47phox binds to the flavocytochrome b₅₅₈ during NADPH oxidase activation. P47phox is the subunit responsible for transporting the cytosolic complex

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

6

(p47phox-p67phox-p40phox) from the cytosol to the membrane during oxidase activation, and for organizing the different NADPH oxidase subunits. In intact cells, p47phox is extensively phosphorylated [13]. P67phox is composed of 526 amino acids, with two SH3 domains, four tetratricopeptide-rich regions and a proline-rich region [7, 12]. P67phox interacts with Rac1/2 and flavocytochrome b₅₅₈ and can regulate its catalytic activity via a sequence called the activation domain [14]. P67phox is phosphorylated on serine and threonine residues by PKC-dependent and PKC-independent pathways [15]. P40phox is a 339-amino-acid protein which was initially identified through its binding to p67phox. It contains one SH3 domain and one PX domain. P40phox is phosphorylated on serine 315 and threonine 154 by a PKC-dependent mechanism [16]. Rac2 is the most abundant rac protein in human neutrophils, but rac1 (92% homologous with Rac2) is also present [12].

3. Activation of the phagocyte NADPH oxidase

3.1. Activation in intact neutrophils

During neutrophil activation, 10-20% of cytosolic NADPH oxidase components migrate to the plasma membrane, where they bind to flavocytochrome b₅₅₈ [7-9]. In intact cells, NADPH oxidase activation is accompanied by phosphorylation of p47phox, p67phox, p40phox, p22phox and gp91phox, along with several protein-protein interactions [10-14]. NADPH oxidase activation in phagocytes can be induced by a large number of particulate and soluble agents such as opsonized bacteria, opsonized zymosan, latex particles, formylated peptides such as formyl-Met-Leu-Phe (fMLF), and

1
2
3
4
5 also by pharmacological compounds such as calcium ionophores and PKC activators
6
7 such as phorbol esters [17]. Other agents, such as pro-inflammatory cytokines (TNF α ,
8
9 GM-CSF, IL-8, etc.) do not activate NADPH oxidase in neutrophils but instead induce
10
11 a state of hyper-responsiveness to subsequent stimulation of NADPH oxidase and ROS
12
13 production by agents such as fMLF, a process known as “priming” [17]. This
14
15 phenomenon of “priming” or oxidative burst initiation is also observed *in vivo*, where it
16
17 may play an important role in physiological regulation of bactericidal activity and also
18
19 in host tissue injury in some inflammatory diseases.
20
21

22
23
24 During neutrophil stimulation, p47phox is phosphorylated on multiple sites in its
25
26 carboxy-terminal portion, including serines 303 to 379, which play a central role in
27
28 NADPH oxidase activation and regulation [13]. In human neutrophils, among the
29
30 various protein kinases involved in the regulation of NADPH oxidase activity, the PKC
31
32 family appears to play a major role in the activation [13,17]. Proinflammatory cytokines
33
34 such as GM-CSF and TNF α induce partial phosphorylation of p47phox on Ser345 [13,
35
36 18]. Phosphorylation of p47phox on Ser345 represents a critical mechanism in the
37
38 priming of ROS production by neutrophils at inflammatory sites. Thus, this site may be
39
40 considered as a “priming site”. P47phox phosphorylation could potentially induce
41
42 conformational changes that initiate assembly of the active enzyme via interaction of
43
44 the SH3 domain with the proline-rich region of p22phox [12, 17]. In resting conditions
45
46 the two SH3 domains of p47phox interact intramolecularly with the auto-inhibitory
47
48 region in the non phosphorylated protein [7, 8]. This interaction switches to the
49
50 p22phox-polyproline sequence when the enzyme is activated by phosphorylation [8].
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

3.2. NADPH oxidase activation in cell-free systems

NADPH oxidase can be activated in a cell-free system by mixing cytosol and plasma membranes isolated from resting neutrophils or macrophages in the presence of Mg^{++} , GTP and an anionic amphiphile such as arachidonic acid or sodium dodecyl sulfate, which are believed to mimic phosphorylation by providing negative charges [19]. Active NADPH oxidase can also be reconstituted from recombinant or highly purified cytochrome b558, p47phox, p67phox and Rac proteins [20]. P40phox is not required for NADPH oxidase activation in a cell-free system, although it enhances NADPH oxidase activation in intact cells. This cell-free system can also be activated by protein kinase C instead of anionic amphiphile agents [21] and by physiological concentrations of phosphatidic acid [22]. This system has been used to examine the effect of various peptide inhibitors on NADPH oxidase activation.

4. Homologues of phagocyte NADPH oxidases (NOXs)

Almost 30 years after the discovery of gp91phox, several homologues of this catalytic subunit have been described in human tissues such as lung, kidney and colon, and in various cell types (epithelial cells, endothelial cells, vascular smooth muscle cells) [6, 23]. These homologues have been cloned and grouped together under the acronym NOX, for NADPH oxidase (NOX1 to NOX5), or Duox, for dual oxidase (Duox1 and Duox2). NOX2 (gp91phox) is not restricted to phagocytes, as it is also expressed, albeit at lower levels, in endothelial cells, B and T lymphocytes, neurons, and other cell types

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

9

[23]. The main difference between phagocytic gp91phox/NOX2 and its homologues resides in the fact that ROS are produced in much smaller amounts by the new homologues. The other difference lies in their regulation, including the nature of the cytosolic subunits and their requirement. These new findings suggest that ROS might be involved in several cellular functions such as local tissue-specific bactericidal activity (in colon or lung) and intracellular signaling. The NOX1 and NOX3 homologues are regulated by two NOX regulatory proteins called NOX organizer 1 (NOXO1) and NOX activator 1 (NOXA1) [24, 25]. These are the respective homologues of p47phox and p67phox. Like p47phox, NOXO1 ‘organizes’ the assembly of the fully active NOX1 enzyme complex. Indeed, it recruits NOXA1 to the membrane-bound NOX1 catalytic subunit through its interaction with p22phox and with membrane phosphoinositides [26, 27]. The small G protein Rac1 is also clearly involved in NOX1 activation, through its interaction with NOX activator 1.

5. Phagocyte NADPH oxidase inhibition

5.1. Chemical (non peptide) inhibitors

Many chemicals are known to inhibit ROS production by the phagocyte NADPH oxidase. Twenty years ago, Cross [28] listed numerous molecules with this effect, although few of them directly interact with or inhibit NADPH oxidase [29]. One of the first inhibitors of NADPH oxidase to be identified, and which is still widely used, is diphenylene iodonium (DPI), which inhibits electron transport by gp91phox/NOX2 [30]. This molecule is a flavoprotein inhibitor and is therefore non specific for NOX2.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

It inhibits not only other NOXs and DUOXs but also NO synthase and probably other flavoproteins [31]. However, in animal models, DPI inhibits ROS production and has an anti-arthritic effect [32]. It has been shown to reduce ethanol-induced liver inflammation in mice [33], and to inhibit pancreatic inflammation and fibrosis [34].

Apocynin (4-hydroxy-3-methoxyacetophenone-substituted), a natural molecule structurally related to vanillin, inhibits the NADPH oxidase [35, 36]. It was reported to target p47phox, and its effect requires a peroxidase such as MPO [37]. It might be more specific for NOX2 but can also inhibit NOX1 *via* NOXO1 in the presence of peroxidase. Apocynin also scavenges ROS, making it non specific for NOX2 [36, 38]. In vivo, apocynin was shown to attenuate collagen-induced arthritis in rats, to lower IL-6 levels, and to reduce joint swelling [39] and zymosan-induced arthritis and inflammation in mice [40]. Apocynin also has other beneficial effects in vivo [41, 36].

Other molecules such as phenylarsine oxide (PAO), a sulfhydryl reagent for vicinal or proximal thiol groups, and 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF), inhibit NADPH oxidase by preventing assembly of the complex [42, 43], but are also known for their inhibitory effects on other enzymes. PAO is a phosphotyrosine phosphatase inhibitor and AEBSF is a serine protease inhibitor. In rats, PAO inhibits ROS production and also attenuates LPS- and carrageenan-induced inflammation [44]. Many other small molecules have been shown to inhibit the phagocyte NADPH oxidase and other NOXs [45], but there are currently no specific chemical inhibitors for the phagocyte NADPH oxidase. Peptide inhibitors could be more specific than chemical inhibitors because they are derived from specific subunit sequences. In the following

part of the article we describe peptide inhibitors derived from each subunit described in the literature and discuss their specificity.

5.2. Peptide inhibitors

Gp91phox-derived inhibitory peptides. Peptides derived from gp91phox/NOX2 have been used to inhibit NADPH oxidase. The first such peptides were the NOX2 carboxy-terminal peptides RGVHFIF (amino acids 559-565) and SNSSEGPRGVHFIFNKEN (amino acids 552-569), which inhibit phagocyte NADPH oxidase activation in cell-free systems (50% inhibitory concentration (IC_{50}) = 32 μ M) and, at higher concentrations, in electropermeabilized neutrophils [46-48]. Leusen and co-workers [49], showed that a point mutation of gp91phox (D500G) in X-linked chronic granulomatous disease patients resulted in an inactive NADPH oxidase and failure of p47phox/p67phox to translocate to membranes, and thereby identified a gp91phox/p47phox interaction domain encompassing D500 in gp91phox. The peptide sequence FAVHHDEEKDVITG, mimicking the 491-504 amino acids domain of gp91phox, inhibited superoxide generation in a cell-free system (IC_{50} = 10 μ M) and also prevented membrane translocation of p47phox and p67phox. Using a random-sequence peptide phage display library technique, DeLeo et al., identified several potential sites of interaction between p47phox and cytochrome b558 [50]. A peptide mimicking one gp91phox/p47phox interaction sequence, corresponding to amino acids 77-93 (FLRGSSACCSTRVRRQL), had a potent inhibitory effect on human NADPH oxidase (IC_{50} = 1 μ M). Another peptide, corresponding to amino acids 86-102, had a

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

12

potent inhibitory effect, with an EC₅₀ of 2 μM [51]. Later, Rey et al., identified the corresponding sequence in mouse gp91phox and called it “gp91phox ds”, for gp91phox docking sequence [52]. They added a translocating TAT peptide (gp91ds-tat: RKKRRQRRR-CSTRIRRQL) to make it cell-permeable (see next section), and showed that it inhibited ROS production in neutrophils and mouse aorta, and also limited the increase in blood pressure elicited by an infusion of angiotensin II in mice [52]. Furthermore, Gp91ds-tat inhibited ROS production in aged rats [41], lowered proatherogenic molecule levels in rats [53], and attenuated neurovascular dysfunction in aged mice [54]. It is noteworthy that this gp91phox/NOX2 sequence is conserved in NOX1 and NOX4, meaning that it is not specific for the phagocyte NADPH oxidase/NOX2 but could act as a NOX1, NOX2 and NOX4 inhibitor. However, this peptide inhibits NOX2 in cells, such as phagocytes, that express only this enzyme.

Park et al., showed that peptides corresponding to gp91phox amino acid residues 27-46, 87-100, 282-296, 304-321, 434-455 and 559-565 inhibited superoxide generation in a cell-free system with respective IC₅₀ values of 34 μM, 40 μM, 30 μM, 35 μM, 25 μM and 53 μM [55]. A peptide corresponding to the predicted NADPH binding site in gp91phox also inhibited superoxide production in a cell-free system. The minimum sequence essential for this inhibitory effect consisted of amino acids 420-425 (KSVWYK) and has an IC₅₀ of 30 μM [56]. Interestingly, unlike other peptides that inhibit NADPH oxidase, this peptide was effective even when added after system activation. Kao et al., identified amino acids 419-430 (ILKSVWYKCNN) as a Rac interaction site within NOX2, and generated a cell-permeant peptide by adding a TAT

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

13

sequence [57]. When used at 20 μM , this peptide inhibited ROS production in neutrophils stimulated by fMLF or PMA. This NOX2-Rac binding domain is conserved in NOX1 and NOX3 but not in NOX4, NOX5 or DUOXs, making it selective for NOX1, NOX2 and NOX3. Figure 4 represents the amino acid sequence of gp91phox/NOX2 and indicates the locations of the major inhibitory peptides. The regions covered by these peptides have more than 60% homology with NOX1, NOX2, NOX4 and NOX5, meaning that these peptides might also affect these homologues. The reason for this lack of specificity is that these peptides were identified before the discovery of NOX homologues. However, there are still several other NOX2 specific sequences which could be tested in order to identify specific inhibitory peptides.

P22phox-derived inhibitory peptides. Nakanishi et al., first showed that the P22phox peptide AGGPPGGPQVNPIPVTDEVV (amino acids 175-194) inhibited superoxide production in a cell-free system, with an IC_{50} of 36 μM , and that it bound to p47phox [47]. A second peptide, corresponding to p22phox residues 82-95 (PFTRNYYVRAVLHL), was then found to inhibit superoxide production with an IC_{50} of 13 μM in a cell-free system consisting of solubilized neutrophil membranes and cytosol [58]. Using a “peptide walking” technique, Pick’s group [59], identified peptides located in p22phox domains corresponding to amino acids 9-23, 31-45, 47-61, 85-99 and 113-127, which inhibited NADPH oxidase activation in a cell-free system composed of macrophage membranes and recombinant proteins, with respective IC_{50} values of 5.7, 3.0, 4.6, 2.0 and 3.0 μM . As p22phox is a subunit common to all NOXs,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

14

p22phox-derived peptides are unlikely to specifically inhibit a particular type of NOX. Figure 5 represents the amino acid sequence of p22phox and the locations of the major inhibitory peptides.

P47phox-derived inhibitory peptides. P47phox sequences have also been used to inhibit NADPH oxidase activation in a cell-free system or in electropermeabilized neutrophils. The p47phox peptide AYRRNSVRFL (amino acids 323-332) inhibits p47phox phosphorylation, p47phox translocation and NADPH oxidase activation in a cell-free system ($IC_{50} = 54 \mu M$) [60, 61]. This peptide may compete either for p47phox phosphorylation, by acting as a pseudosubstrate for protein kinases, or for p47phox interaction with flavocytochrome b_{558} or p67phox [61]. A synthetic peptide comprising the amino acid sequence 323-332, corresponding to residues 314-331 (RSRKRLSQDAYRRNSVRF), also inhibits p47phox phosphorylation, p47phox translocation and NADPH oxidase activation in human neutrophils [62]. DeLeo et al., identified sites of p47phox interaction with flavocytochrome b_{558} and used the corresponding peptides to inhibit NADPH oxidase [61]. In addition to peptide 323-332, they found that peptides corresponding to amino acids 315-332 and 334-347 inhibited superoxide production in a cell-free system and in electropermeabilized neutrophils, with respective IC_{50} values of $15 \mu M$ and $18 \mu M$. Morozov et al., used the peptide-walking technique to map p47phox functional domains involved in NADPH oxidase activation [63]. They showed that peptides corresponding to amino acids 5-19 ($IC_{50} = 10.6 \mu M$), 17-31 ($IC_{50} = 8.8 \mu M$), 105-119 ($IC_{50} = 10.3 \mu M$), 149-163 ($IC_{50} = 10.9 \mu M$),

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

15

193-207 ($IC_{50}= 8.5 \mu M$), 305-319 ($IC_{50}= 11.5 \mu M$) and 325-339 ($IC_{50}= 3.4 \mu M$) inhibited NADPH oxidase activation in a cell-free system. The most effective was the peptide corresponding to amino acids 325-339, which overlaps with the peptide described above by other investigators [60-62]. Three other inhibitory peptides are located in the PX domain (amino acids 5-19, 17-31 and 105-119), two in the SH3 domain (amino acids 149-163 and 193-207), and two in the carboxy-terminal phosphorylated domain (amino acids 305-319 and 325-339). P47phox is heavily phosphorylated in neutrophils, and this phosphorylation plays a major role in NADPH oxidase activation. Two peptides corresponding to p47phox phosphorylated sites (amino acids 301-320 and 314-335) inhibit NADPH oxidase activation ($IC_{50}= 7$ and $6.7 \mu M$ respectively) by inhibiting p47phox interaction with p22phox and its membrane translocation [64]. Among the p47phox phosphorylated sites, Ser345 plays a key role in NADPH oxidase hyperactivation or priming by pro-inflammatory cytokines such as $TNF\alpha$ and GM-CSF, and also in inflammatory diseases such as rheumatoid arthritis [18] and intestinal inflammation [65]. Interestingly, a TAT-peptide sequence containing Ser345 (amino acids 334-347) was shown to inhibit NADPH oxidase hyper-activation in human neutrophils induced by $TNF\alpha$ and GM-CSF, and hyperactivation of PMN from synovial fluid of RA patients, while preserving the physiological ability of bacterial N-formyl peptide to activate neutrophils [18]. Figure 6 represents the sequence of p47phox and the sites of the major inhibitory peptides. Since the PX and SH3 domains are conserved between p47phox and NOXO1, peptides located in these domains are unlikely to be specific for NOX2. However, the AIR domain of p47phox

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

16

(amino acids 286-340) is missing in NOXO1, and peptides derived from this sequence could therefore represent good candidates for developing very specific inhibitors of the phagocyte NADPH oxidase, the activity of which requires the organizer subunit p47phox.

Rac1-derived inhibitory peptides. The Rac1 peptide, corresponding to aa 178-188, inhibited NADPH oxidase activity in a cell-free system, with an IC₅₀ of about 10 μM [66, 67]. Interestingly, the corresponding peptide sequence of Rac2 (aa 178-188) had no effect. The Rac1 sequence could thus be used to study the specific role of Rac1. Mapping of Rac1 functional domains by peptide walking has identified several inhibitory peptides (residues 73-81, 103-107, 123-133, 163-169 and 183-188) [68]. Like p22phox, Rac1 is a subunit common to all NOXs, making it unlikely that Rac1-derived peptides would have a specific effect on a particular NOX.

P67phox- and p40phox-derived inhibitory peptides. To our knowledge, no peptide sequences derived from p67phox or p40phox have yet been shown to inhibit the phagocyte NADPH oxidase. One possible reason is that p67phox was long considered to be an unstable protein with only a minor function in NADPH oxidase activation. However, in 1998, Han et al., showed that p67phox has an activation domain (amino acids 199-210) [14], and Diekman et al., showed that it binds Rac during activation by its N-terminal region (amino acids 1-199) [69]. These two p67phox sequences might be

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

17
used to develop new competitive inhibitory peptides. The reason for the lack of p40phox-derived peptides may be that p40phox is not required for NADPH oxidase activation in the cell-free system, making it more difficult to assess the effect of inhibitory peptides in intact cells.

Inhibitory peptides not derived from NADPH oxidase components. A proline- and arginine- (PR) rich antibacterial peptide designated PR-39 (because it contains 19 prolines and 10 arginines) inhibits NADPH oxidase activity ($IC_{50} = 1 \mu M$) by targeting the interaction of the p47phox SH3 domain with p22phox [70]. This peptide has protective effects in experimental myocardial ischemia-reperfusion [71]. Because SH3 domain/polyproline region interaction is involved in several protein/protein interactions, this peptide might inhibit processes other than NADPH oxidase activation.

A cell-permeable dominant negative peptide (DN-Ets-1-TAT) derived from Ets-1, a transcriptional regulator of p47phox, was found to lower angiotensin II-induced p47phox expression and ROS production in vitro, and also to attenuate medial hypertrophy of the thoracic aorta in mice [72]. This strategy targets p47phox expression and not NADPH oxidase activation. Inhibition of NADPH oxidase expression is not a suitable strategy for neutrophils, because p47phox is already expressed in mature neutrophils; however, this peptide might alter p47phox expression in monocytes, macrophages or other cells which continuously express p47phox.

Qin et al. showed that a tripeptide (GGF) contained in the dynorphin opioid peptide inhibited microglial NADPH oxidase at femtomolar concentrations and had

neuroprotective and anti-inflammatory effects [73]. The mechanism of action of this peptide is not known.

6-Peptide delivery into living cells

The main obstacle to the use of peptides to inhibit NADPH oxidase in intact living cells is their inability to cross the plasma membrane lipid bilayer. The use of cell-penetrating peptides (CPPs) or protein transduction domains (PTDs) is an attractive approach to this problem [74]. The most widely used CPPs are derived from the human immunodeficiency virus (HIV1) transactivator protein TAT, the *Drosophila* transcription factor antennapedia protein, and the herpes simplex virus (HSV) type 1 protein VP22 [75]. Although the mechanism of peptide transduction is controversial, these peptides can deliver biologically active proteins, DNA, RNA, liposomes and nanoparticles across plasma membranes [74,75]. Several NADPH oxidase peptide inhibitors have already been coupled to TAT peptide and have been shown to inhibit ROS production *in vitro* and *in vivo* [18,52-54,57,72].

7-Conclusion and future perspectives

NADPH oxidases/NOXs have essential roles in many physiological processes, including innate immunity, cell proliferation, gene expression, blood pressure regulation, antigen presentation and intracellular signaling. However, excessive ROS production by NADPH oxidases, and especially by the phagocyte NADPH oxidase NOX2, has been implicated in many inflammatory diseases, such as rheumatoid

1
2
3
4 arthritis, inflammatory bowel disease, acute respiratory distress syndrome, sepsis,
5
6 diabetic complications, cardiovascular diseases, ischemic tissue injury and
7
8 neurodegenerative diseases, in which ROS are believed to cause direct tissue insult.
9
10 Thus, pharmacological targeting of the phagocyte NADPH oxidase/NOX2 might be
11
12 beneficial in patients with these disorders. No specific chemical inhibitors for NOX2
13
14 have so far been identified, and peptide-based inhibitors appear to be the most
15
16 promising candidates, provided the target sequence is specific for a particular
17
18 phagocyte NADPH oxidase component. The best targets for NADPH oxidase inhibitors
19
20 are gp91phox/NOX2, p47phox and p67phox, because their expression is more specific
21
22 for phagocytes. This tends to rule out the use of peptides derived from p22phox and
23
24 Rac1/2, which are components common to all NOXs.
25
26
27
28
29
30

31 The main problem with inhibitory peptides used to be their cell delivery, but this can
32
33 now be achieved by coupling to cell-permeable peptides such as TAT or antennapedia
34
35 peptide. Several cell-permeant peptide antagonists of NOX2 have already been shown
36
37 to inhibit ROS production in vitro and in vivo, and have also served to identify new
38
39 biological functions of the NADPH oxidase system. The other problem with peptides is
40
41 their stability in live organisms. Interestingly, subcutaneous or intravenous infusion of
42
43 NOX2-inhibitory peptides has been shown to attenuate vascular disorders in
44
45 experimental animals. Oral administration is unlikely to provide efficient peptide
46
47 delivery because of the hostile gastrointestinal environment. Finally, candidate
48
49 inhibitors should be specific for the phagocyte NADPH oxidase in order to avoid cross-
50
51 inhibition. The ideal NADPH oxidase inhibitor would prevent hyper-activity while
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

20

preserving the physiological functions of this key element in host defenses, as described above for the peptide derived from Ser345-p47phox sequence. Drugs that prevent NADPH oxidase priming and ROS over-production would be particularly valuable.

Accepted Manuscript

Acknowledgements

This work was supported by grants from Agence Nationale de la Recherche (ANR), Arthritis Fondation Courtin, INSERM and CNRS.

Accepted Manuscript

References

1. Babior BM. Oxidants from phagocytes: agents of defense and destruction. *Blood* 1984;64:959-66.
2. Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. *Blood* 1998; 92 :3007-17.
3. El-Benna J, Dang PM, Gougerot-Pocidallo MA, Elbim C. Phagocyte NADPH oxidase: a multicomponent enzyme essential for host defenses. *Arch Immunol Ther Exp (Warsz)* 2005;53:199-206.
4. Roos D, De Boer M, Kuribayashi F, Meischl, Weening RS, Segal AW, Ahlin A, Nemet K, Hossle JP, Bernatowska-Matuszkiewicz and Middleton-Price H: Mutations in the X-Linked and Autosomal recessive forms of chronic granulomatous disease. *Blood* 1996; 87: 1663-81.
5. Babior BM. Phagocytes and oxidative stress. *Am. J. Med* 2000; 109:33-44.
6. Lambeth JD. Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. *Free Radic. Biol. Med.* 2007; 43: 332-47.

- 1
2
3
4
5
6
7 7. Groemping Y, Rittinger K. Activation and assembly of the NADPH oxidase : a
8
9 structural perspective. *Biochem J.* 2005; 386: 401-16.
10
- 11
12
13
14 8. Babior BM. NADPH Oxidase: an update. *Blood* 1999, 93: 1464-76.
15
16
- 17
18
19 9. Vignais PV. The superoxide-generating NADPH oxidase: structural aspects
20 and activation mechanism. *Cell Mol Life Sci* 2002; 59 :1428-59.
21
22
- 23
24
25
26 10. Regier DS, Waite KA, Wallin R, McPhail L.C.: A phosphatidic acid-activated
27 protein kinase and conventional protein kinase C isoforms phosphorylate p22(phox), an
28 NADPH oxidase component. *J Biol Chem* 1999;274:36601-08.
29
30
- 31
32
33
34 11. Raad H, Paclet MH, Boussetta T, Kroviarski Y, Morel F, Quinn MT,
35 Gougerot-Pocidallo MA, Dang PM, El-Benna. Regulation of the phagocyte NADPH
36 oxidase activity: phosphorylation of gp91phox/NOX2 by protein kinase C enhances its
37 diaphorase activity and binding to Rac2, p67phox, and p47phox. *FASEB J* 2009; 23:
38 1011-22.
39
40
41
42
43
44
45
46
47
- 48
49
50 12. DeLeo FR and Quinn MT. Assembly of the phagocyte NADPH oxidase:
51 molecular interaction of oxidase proteins. *J Leuk Biol* 1996; 60: 677-91.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 13.** El-Benna J, Dang PM, Gougerot-Pocidal MA, Marie JC, Braut-Boucher F. p47phox, the phagocyte NADPH oxidase/NOX2 organizer: structure, phosphorylation and implication in diseases. *Exp Mol Med* 2009; 41:217-25.
- 14.** Han CH, Freeman JL, Lee T, Motalebi SA, Lambeth JD. Regulation of the neutrophil respiratory burst oxidase. Identification of an activation domain in p67(phox). *J Biol Chem.* 1998;273:16663-8.
- 15.** Dang PM, Morel F, Gougerot-Pocidal MA, Benna JE. Phosphorylation of the NADPH oxidase component p67(PHOX) by ERK2 and P38MAPK: selectivity of phosphorylated sites and existence of an intramolecular regulatory domain in the tetratricopeptide-rich region. *Biochemistry* 2003; 42:4520-6.
- 16.** Bouin AP, Grandvaux N, Vignais PV, Fuchs A. p40(phox) is phosphorylated on threonine 154 and serine 315 during activation of the phagocyte NADPH oxidase. Implication of a protein kinase C-type kinase in the phosphorylation process. *J Biol Chem* 1998; 273: 30097-103.
- 17.** El-Benna J, Dang PM, Gougerot-Pocidal MA. Priming of the neutrophil NADPH oxidase activation: role of p47phox phosphorylation and NOX2 mobilization to the plasma membrane. *Semin Immunopathol* 2008; 30:279-89.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 25
18. Dang PM, Stensballe A, Boussetta T, Raad H, Dewas C, Kroviarski Y, Hayem G, Jensen ON, Gougerot-Pocidallo MA, El-Benna J. A specific p47phox -serine phosphorylated by convergent MAPKs mediates neutrophil NADPH oxidase priming at inflammatory sites. *J Clin Invest* 2006; 116: 2033-43.
19. Bromberg Y, Pick E. Activation of NADPH-dependent superoxide production in a cell-free system by sodium dodecyl sulfate. *J Biol Chem* 1985;260:13539-45.
20. Dagher M.C. and Pick E. Opening the black box: lessons from cell-free systems on the phagocyte NADPH-oxidase. *Biochimie* 2007; 89: 1123-32.
21. El-Benna J, Park JW, Ruedi JM, Babior BM. Cell-free activation of the respiratory burst oxidase by protein kinase C. *Blood Cells Mol Dis* 1995; 21: 201-6.
22. Erickson RW, Langel-Peveri P, Traynor-Kaplan AE, Heyworth PG, Curnutte JT. Activation of human neutrophil NADPH oxidase by phosphatidic acid or diacylglycerol in a cell-free system. Activity of diacylglycerol is dependent on its conversion to phosphatidic acid. *J Biol Chem* 1999; 274: 22243-50.
23. Bedard K and Krause KH The NOX Family of ROS-Generating NADPH oxidases: Physiology and pathophysiology. *Physiol Rev* 2007; 87: 245-313.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 26
24. Geiszt M, Lekstrom K, Witta J and Leto TL. Proteins homologous to p47phox and p67phox support superoxide production by NAD(P)H oxidase 1 in colon epithelial cells. *J Biol Chem* 2003; 278: 20006-12.
25. Bánfi B, Clark RA, Steger K, Krause KH. Two novel proteins activate superoxide generation by the NADPH oxidase NOX1. *J Biol Chem* 2003; 278: 3510-3.
26. Cheng G, Lambeth JD. NOXO1, regulation of lipid binding, localization, and activation of Nox1 by the Phox Homology (PX) domain. *J Biol Chem* 2004; 279: 4737-42.
27. Takeya R, Ueno N, Kami K, Taura M, Kohjima M, Izaki T, Nunoi H, Sumimoto H. Novel human homologues of p47phox and p67phox participate in activation of superoxide-producing NADPH oxidases. *J Biol Chem* 2003; 278:25234-46.
28. Cross A.R. Inhibitors of the leukocyte superoxide generating oxidase: mechanisms of action and methods for their elucidation. *Free Radic Biol Med* 1990; 8:71-93.
29. Lambeth JD, Krause KH, Clark RA. NOX enzymes as novel targets for drug development. *Semin Immunopathol* 2008; 30:339-63.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 30.** Hancock JT, Jones OT. The inhibition by diphenyleneiodonium and its analogues of superoxide generation by macrophages. *Biochem J* 1987; 242:103-7.
- 31.** Stuehr DJ, Fasehun OA, Kwon NS, Gross SS, Gonzalez JA, Levi R, Nathan CF. Inhibition of macrophage and endothelial cell nitric oxide synthase by diphenyleneiodonium and its analogs. *FASEB J* 1991; 5:98-103.
- 32.** Miesel R, Kurpisz M, Kroger H. Suppression of inflammatory arthritis by simultaneous inhibition of nitric oxide synthase and NADPH oxidase. *Free Radic Biol Med* 1996; 20:75-81.
- 33.** Gustot T, Lemmers A, Moreno C, Nagy N, Quertinmont E, Nicaise C, Franchimont D, Louis H, Devière J, Le Moine O. Differential liver sensitization to toll-like receptor pathways in mice with alcoholic fatty liver. *Hepatology* 2006; 43:989-1000.
- 34.** Masamune A, Watanabe T, Kikuta K, Satoh K, Shimosegawa T. NADPH oxidase plays a crucial role in the activation of pancreatic stellate cells. *Am. J. Physiol. Gastrointest Liver Physiol* 2008; 294:G99-G108.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
35. Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. *Am J Respir Cell Mol Biol* 1994; 11:95-102.
36. Stefanska J, Pawliczak R. Apocynin: molecular aptitudes. *Mediators Inflamm* 2008;106507, Article ID 106507, 10 pages, doi:10.1155/2008/106507.
37. Ximenes VF, Kanegae MP, Rissato SR, Galhiane MS. The oxidation of apocynin catalyzed by myeloperoxidase: proposal for NADPH oxidase inhibition. *Arch Biochem Biophys.* 2007;457:134-41.
38. Heumüller S, Wind S, Barbosa-Sicard E, Schmidt HH, Busse R, Schröder K, Brandes RP. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. *Hypertension* 2008; 51: 211-7.
39. 't Hart BA, Simons JM, Knaan-Shanzer S, Bakker NP, Labadie RP. Antiarthritic activity of the newly developed neutrophil oxidative burst antagonist apocynin. *Free Radic Biol Med* 1990; 9:127-31.
40. Hougee S, Hartog A, Sanders A, Graus YM, Hoijer MA, Garssen J, van den Berg WB, van Beuningen HM, Smit HF. Oral administration of the NADPH-oxidase

1
2
3
4 inhibitor apocynin partially restores diminished cartilage proteoglycan synthesis and
5
6
7 reduces inflammation in mice. *Eur J Pharmacol* 2006; 531:264-9.
8
9

10
11
12 **41.** Zhou X, Bohlen HG, Unthank JL, Miller SJ. Abnormal nitric oxide production
13
14 in aged rat mesenteric arteries is mediated by NAD(P)H oxidase-derived peroxide. *Am*
15
16 *J Physiol Heart Circ Physiol* 2009; 297:H2227-33.
17
18

19
20
21 **42.** Le Cabec V, Maridonneau-Parini I. Complete and reversible inhibition of
22
23 NADPH oxidase in human neutrophils by phenylarsine oxide at a step distal to
24
25 membrane translocation of the enzyme subunits. *J Biol Chem* 1995; 270:2067-73.
26
27

28
29
30
31 **43.** Diatchuk V, Lotan O, Koshkin V, Wikstroem P, Pick E. Inhibition of NADPH
32
33 oxidase activation by 4-(2-aminoethyl)-benzenesulfonyl fluoride and related
34
35 compounds. *J Biol Chem* 1997; 272:13292-301.
36
37

38
39
40
41 **44.** Roussin A, Le Cabec V, Lonchamp M, De Nadaï J, Canet E, Maridonneau-
42
43 Parini I. Neutrophil-associated inflammatory responses in rats are inhibited by
44
45 phenylarsine oxide. *Eur J Pharmacol* 1997;322:91-6.
46
47

48
49
50
51 **45.** Jaquet V, Scapozza L, Clark RA, Krause KH, Lambeth JD. Small-molecule
52
53 NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. *Antioxid*
54
55 *Redox Signal* 2009; 11:2535-52.
56
57

- 1
2
3
4
5
6
7 **46.** Rotrosen D, Kleinberg ME, Nunoi H, Leto T, Gallin JI, Malech HL. Evidence
8 for a functional cytoplasmic domain of phagocyte oxidase cytochrome b558. *J Biol*
9 *Chem* 1990; 265:8745-50.
10
11
12
13
14
15
16
17 **47.** Nakanishi A, Imajoh-Ohmi S, Fujinawa T, Kikuchi H, Kanegasaki S. Direct
18 evidence for interaction between COOH-terminal regions of cytochrome b558 subunits
19 and cytosolic 47-kDa protein during activation of an O(2⁻)-generating system in
20 neutrophils. *J Biol Chem* 1992; 267: 19072-4.
21
22
23
24
25
26
27
28
29 **48.** DeLeo FR, Jutila MA, Quinn MT. Characterization of peptide diffusion into
30 electroporabilized neutrophils. *J Immunol Methods* 1996; 198:35-49.
31
32
33
34
35
36 **49.** Leusen JH, de Boer M, Bolscher BG, Hilarius PM, Weening RS, Ochs HD,
37 Roos D, Verhoeven AJ. A point mutation in gp91-phox of cytochrome b558 of the
38 human NADPH oxidase leading to defective translocation of the cytosolic proteins p47-
39 phox and p67-phox. *J Clin Invest* 1994; 93 :2120-6.
40
41
42
43
44
45
46
47
48 **50.** DeLeo FR, Yu L, Burritt JB, Loetterle LR, Bond CW, Jesaitis AJ, Quinn MT.
49 Mapping sites of interaction of p47-phox and flavocytochrome b with random-sequence
50 peptide phage display libraries. *Proc Natl Acad Sci USA* 1995; 92:7110-4.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 51.** Yu L, Cross AR, Zhen L, Dinauer MC. Functional analysis of NADPH oxidase in granulocytic cells expressing a delta488-497 gp91(phox) deletion mutant. *Blood* 1999; 94:2497-504.
- 52.** Rey FE, Cifuentes ME, Kiarash A, Quinn MT, Pagano PJ. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O₂(⁻) and systolic blood pressure in mice. *Circ Res* 2001; 31:408-14.
- 53.** Zhou MS, Hernandez Schulman I, Pagano PJ, Jaimes EA, Raj L. Reduced NAD(P)H oxidase in low renin hypertension: link among angiotensin II, atherogenesis, and blood pressure. *Hypertension* 2006; 47:81-6.
- 54.** Park L, Zhou P, Pitstick R, Capone C, Anrather J, Norris EH, Younkin L, Younkin S, Carlson G, McEwen BS, Iadecola C. Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. *Proc Natl Acad Sci U S A.* 2008; 105:1347-52.
- 55.** Park MY, Imajoh-Ohmi S, Nuno H, Kanegasaki S. Synthetic peptides corresponding to various hydrophilic regions of the large subunit of cytochrome b558 inhibit superoxide generation in a cell-free system from neutrophils. *Biochem Biophys Res Commun* 1997; 234:531-6.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 56.** Tsuchiya T, Imajoh-Ohmi S, Nunoi H, Kanegasaki S. Uncompetitive inhibition of superoxide generation by a synthetic peptide corresponding to a predicted NADPH binding site in gp91-phox, a component of the phagocyte respiratory oxidase. *Biochem Biophys Res Commun* 1999; 257:124-8.
- 57.** Kao YY, Gianni D, Bohl B, Taylor RM, Bokoch GM. Identification of a conserved Rac-binding site on NADPH oxidases supports a direct GTPase regulatory mechanism. *J Biol Chem* 2008; 283:12736-46.
- 58.** Park MY, Imajoh-Ohmi S, Nunoi H, Kanegasaki S. Peptides corresponding to the region adjacent to His-94 in the small subunit of cytochrome b558 inhibit superoxide generation in a cell-free system from human neutrophils. *Biochem Biophys Res Commun* 1994; 204:924-9.
- 59.** Dahan I, Issaeva I, Gorzalczany Y, Sigal N, Hirshberg M, Pick E. Mapping of functional domains in the p22(phox) subunit of flavocytochrome b(559) participating in the assembly of the NADPH oxidase complex by "peptide walking". *J Biol Chem* 2002; 277:8421-32.
- 60.** Nauseef WM, McCormick S, Renee J, Leidal KG, Clark RA. Functional domain in an arginine-rich carboxyl-terminal region of p47phox. *J Biol Chem* 1993; 268:23646-51.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 61.** DeLeo FR, Nauseef WM, Jesaitis AJ, Burritt JB, Clark RA, Quinn MT. A domain of p47phox that interacts with human neutrophil flavocytochrome b558. *J Biol Chem* 1995; 270: 26246-51.
- 62.** Labadia ME, Zu YL, Huang CK. A synthetic peptide containing a predominant protein kinase C site within p47phox inhibits the NADPH oxidase in intact neutrophils. *J Leukoc Biol* 1996; 59:116-22.
- 63.** Morozov I, Lotan O, Joseph G, Gorzalczany Y, Pick E. Mapping of functional domains in p47(phox) involved in the activation of NADPH oxidase by "peptide walking". *J Biol Chem* 1998; 273:15435-44.
- 64.** Huang J, Kleinberg ME. Activation of the phagocyte NADPH oxidase protein p47(phox). Phosphorylation controls SH3 domain-dependent binding to p22(phox). *J Biol Chem* 1999; 274 :19731-37.
- 65.** Boussetta T, Raad H, Lettéron P, Gougerot-Pocidallo MA, Marie JC, Driss F, El-Benna J. Punicic acid a conjugated linolenic acid inhibits TNFalpha-induced neutrophil hyperactivation and protects from experimental colon inflammation in rats. *PLoS One*. 2009; 4:e6458.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66. Kreck ML, Uhlinger DJ, Tyagi SR, Inge KL, Lambeth JD. Participation of the small molecular weight GTP-binding protein Rac1 in cell-free activation and assembly of the respiratory burst oxidase. Inhibition by a carboxyl-terminal Rac peptide. *J Biol Chem* 1994 ;269 :4161-8.
67. Joseph G, Gorzalczany Y, Koshkin V, Pick E. Inhibition of NADPH oxidase activation by synthetic peptides mapping within the carboxyl-terminal domain of small GTP-binding proteins. Lack of amino acid sequence specificity and importance of polybasic motif. *J Biol Chem* 1994; 269:29024-31.
68. Joseph G, Pick E. "Peptide walking" is a novel method for mapping functional domains in proteins. Its application to the Rac1-dependent activation of NADPH oxidase. *J Biol Chem* 1995; 270:29079-82.
69. Diekmann D, Abo A, Johnston C, Segal AW, Hall A. Interaction of Rac with p67phox and regulation of phagocytic NADPH oxidase activity. *Science*. 1994; 265:531-3.
70. Shi J, Ross CR, Leto TL, Blecha F. PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47 phox. *Proc Natl Acad Sci U S A* 1996; 93:6014-18.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 35
71. Ikeda Y, Young LH, Scalia R, Ross CR, Lefer AM. PR-39, a proline/arginine-rich antimicrobial peptide, exerts cardioprotective effects in myocardial ischemia-reperfusion. *Cardiovasc Res* 2001; 49:69-77.
72. Ni W, Zhan Y, He H, Maynard E, Balschi JA, Oettgen P. Ets-1 is a critical transcriptional regulator of reactive oxygen species and p47(phox) gene expression in response to angiotensin II. *Circ Res* 2007; 101:985-94.
73. Qin L, Block ML, Liu Y, Bienstock RJ, Pei Z, Zhang W, Wu X, Wilson B, Burka T, Hong JS. Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress. *FASEB J* 2005; 19:550-7.
74. Jarver P, Langel U. The use of cell-penetrating peptides as a tool for gene regulation. *Drug Discov Today*. 2004; 9:395-402.
75. Brooks H, Lebleu B, Vivès E. Tat peptide-mediated cellular delivery: back to basics. *Adv Drug Deliv Rev*. 2005; 57:559-77.

Figure legends**Figure 1. Predicted structure of gp91phox/NOX2.**

The protein has a short N-terminal cytosolic sequence, 6 transmembrane helices, and one long C-terminal cytosolic tail containing the FAD binding site and one NADPH binding site.

Figure 2. Predicted structure of p22phox.

The protein has an N-terminal cytosolic sequence, 2 transmembrane helices, and one long C-terminal cytosolic tail containing a proline-rich region (PRR) which binds to p47phox SH3 domains.


Figure 3. Predicted structure of p47phox.

The protein has a phox homology (PX) domain, two src homology (SH3) domains, one auto-inhibitory region (AIR) and a proline-rich region (PRR).

Figure 4. Amino acid sequence of human gp91phox/NOX2 and sites of the major inhibitory peptides. Heavily hashed boxes represent predicted transmembrane alpha helices. Also indicated are putative FAD and NADPH binding sites. Bold and underlined sequences represent inhibitory peptides.

Figure 5. Amino acid sequence of p22phox and sites of the major inhibitory peptides. Heavily hashed boxes represent predicted transmembrane alpha helices. Also indicated is the proline-rich region (PRR). Bold and underlined sequences represent inhibitory peptides.

Figure 6. Amino acid sequence of p47phox and sites of the major inhibitory peptides. Black boxes represent the phox homology domain (PX), white boxes the src homology domain 3 (SH3) domains, hashed boxes the auto-inhibitory region (AIR) and the proline-rich region (PRR). Bold and underlined sequences represent inhibitory peptides.



* Inhibitory peptides derived from NADPH oxidase subunits.

Figure 1 (El-Benna et al.)




Figure 1 (El-Benna et al.)




Figure 2 (El-Benna et al.)




Figure 2 (El-Benna et al.)




Figure 3 (EL Benna et al.)




Figure 4 (El-Benna et al.)

1 MGNWAVNEGL SIFVILVWLG LNVFLF VWYY RVDIPPKFF YTRKLLGSAL
51 ALARAPAACL NFNCLMLILLP VCRNLLS FLR GSSACCSTRV RRQLDRNLTF
101 HKMVAWMIAL HSAIHTIAHL FNVEWCVNAR VNSDPYSVA LSELGDRQNE
151 SYLNFAKRI KNPEGGLYLA VTLLAGITGV VITLCLILII TSSTKTIRRS
201 YFEVFWYTHH LFVIFFIGLA IHGAERIVRG QTAESLAVHN ITVCEQKISE
251 WGKIKECPIP QFAGNPPMTW KWIVGPMFLY L CERLVRFWR SQQKVVITKV
301 VTH PFKTIEL QMKKGFKME VGQYIFVKCP KVSLEWHPF **FAD** TLTSAPEEDF
351 FSIHIRIVGD WTEGLFNACG CDKQEFQDAW KLPKIAVDGP FGTASEDVFS
401 YEVVMLVGAG IGVTPFAS IL KSVWYKCNN ATN LKLKKIY FYWLCRDTHA
451 FEWFADLLQL LESQMQRN AGFLSYNIYL TGWDESQANH FAVHHDEEKD
501 VITGLKQKTL YGRPNWDNEF KTIASQHPNT RIGVFLCGPE **FAD** ALAETLSKQS
551 I SNSESPRG VHFIFNKENF

Figure 5 (El-Benna et al.)

1 MGQIEWAM WA NEQALASGLI LITGGIVATA GRFTQWYFGA YSIVAGVFVC
 51 LLEYPRGKRK KGSTMERWGQ KYMTAVVKLF GPFTRNYYVR AVLHLLLSVP
 101 AGFLLATILG TA CLAIASGI YLLAAVRGEO WTPIEPKPRE RPQIGGTIKQ
 151 PPSNPPPRPP AEARKKPSEE EAAVAAGGPP GGPQVNPIPV TDEVV

Figure 6 (El-Benna et al.)

1 MGD**T****FIRHIA LLGFEKRFVP SQHYVYMFLV** KWQDLSEKVV YRRFTEIYEF
 51 HKT**L**KEMFPI EAGAINPENR IIPHL**P**APKW FDGQRAAENR QGTLTEYCGT
 101 LMS**L****PTKISR CPHLLDFKV** RPDDLK**L**PTD NQTKKPETYL MPKD**G**KST**A**T
 151 **DITGPIILOT YRA**IANYEKT SGSE**M**ALSTG DVVEVVEKSE SG**WWFCOMKA**
 201 **KRGWIPA**SFL EPLD**S**PDETE DPEPN**Y**AGEP YVAIKAYTAV EGDEVS**L**L**E**G
 251 EAVEVIHKLL DGWWVIRKDD VTGYFPSMYL QKSGQDVSQA QRQIKRGAPP
 301 **RRSSIRNAHS IHQSRKRLS** QDAYR**R**NSVR FLQ**Q**RRRQAR PGPQSPGSPL
 351 EEERQ**T**QR**S**K P**Q**PAVPPRPS ADLILNRCSE STKRKLASAV